DIAGNOSTIC ASSAYS FOR BREAST CANCER TREATMENT AND PROGRESSION

摘要

The present invention provides for assays that identify women with estrogen receptor alpha expressing breast tumors (ER+ tumors) that are best treated with aromatase inhibitors instead of specific estrogen receptor modulators (SERMs) such as tamoxifen (TAM). In one embodiment, the invention provides for the use of an H222 ELISA to identify those postmenopausal women with ER+ breast tumors that must be treated with aromatase inhibitors because treatment with tamoxifen or other similarly acting SERM will be ineffective.